Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

'Promising' C.diff treatment developed

  • Comment

A new MRSA and Clostridium difficile treatment is being developed by a Scottish biopharmaceutical company.

Researchers at Glasgow-based MGB Biopharma have hailed the MGB BP-3 antibiotic as “extremely promising”.

They claim that the compound is more effective in killing and preventing C.diff bacterium than the commonly used vancomycin.

Presenting their findings at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago, the team said clinical trials of MGB BP-3 are due to take place next year.

MGB Biopharma chief executive officer Dr Miroslav Ravic said: “We are very excited that MGB BP-3 shows such a promising response against this troublesome and difficult-to-treat infection.

“We are committed to developing a specific oral drug for the treatment of Clostridium difficile infections in addition to the progress we are making with an IV drug against MRSA.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs